Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

@article{Klok2013CosteffectivenessOA,
  title={Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.},
  author={Rogier M. Klok and Rose-Marie Lindkvist and Mats Ekelund and Raymond A. Farkouh and David Strutton},
  journal={Clinical therapeutics},
  year={2013},
  volume={35 2},
  pages={119-34}
}
BACKGROUND The introduction of a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) had profound public health effects across the globe. PCV7 vaccination in a national immunization program is generally considered cost-effective and potentially cost-saving. Two new PCVs have been launched, a 10-valent pneumococcal conjugate vaccine (PCV10) and a 13-valent pneumococcal conjugate vaccine (PCV13). OBJECTIVE This article examines the public health and economic effects of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS